Survival in myotonic dystrophy type 1: a long time follow up-study with special reference to gastrointestinal symptoms
Abstract
Background: Myotonic dystrophy type 1 (DM1) is a monogenetic disease affecting many organs. Gastrointestinal symptoms are prevalent and of considerable consequences for affected individuals. The life expectancy is shortened and the objective of the study is to evaluate if gastrointestinal symptoms can predict the outcome of the disease.
Method: Fifty-one patients with DM1 were interviewed regarding symptoms from the gastrointestinal tract in the mid-1990s. Survival of all patients was evaluated in 2023 and the impact of symptoms on survival was assessed.
Results: At the beginning of the study, the mean age was 35.9 years, (median 37.0, 9–63). At the end of the study 47 out of the 51 patients were deceased at a mean age of 53.7 years (median 55.7, 32.5–79.0). Patients with the congenital form of DM1 (n = 6) died at an age of 46.0 years (median 45.2, 40.0–53.6). There was no correlation between the gastrointestinal symptoms and survival.
Conclusion: Albeit prevalent and of considerable clinical consequence, gastrointestinal symptoms are not correlated to survival in myotonic dystrophy type 1.
Downloads
References
2. Olofsson BO, Forsberg H, Andersson S, Bjerle P, Henriksson A, Wedin I. Electrocardiographic findings in myotonic dystrophy. Br Heart J. 1988;59:47–52. doi: 10.1136/hrt.59.1.47
3. Rossolimo G. De la myotonie atrophique. Nouv Iconog Salpetrière. 1902;15:63–77.
4. New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC). Neurology. 2000;54:1218–21. doi: 10.1212/WNL.54.6.1218
5. Groh WJ, Groh MR, Shen C, Monckton DG, Bodkin CL, Pascuzzi RM. Survival and CTG repeat expansion in adults with myotonic dystrophy type 1. Muscle Nerve. 2011;43:648–51. doi: 10.1002/mus.21934
6. Hamel JI, McDermott MP, Hilbert JE, Martens WB, Luebbe E, Tawil R, et al. Milestones of progression in myotonic dystrophy type 1 and type 2. Muscle Nerve. 2022;66:508–12. doi: 10.1002/mus.27674
7. Mathieu J, Allard P, Potvin L, Prevost C, Begin P. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology. 1999;52:1658–62. doi: 10.1212/WNL.52.8.1658
8. Mazzoli M, Ariatti A, Garuti GC, Agnoletto V, Genovese M, Gozzi M, et al. Predictors of prognosis in type 1 myotonic dystrophy (DM1): longitudinal 18-years experience from a single center. Acta Myol. 2020;39:109–20.
9. Reardon W, Newcombe R, Fenton I, Sibert J, Harper PS. The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects. Arch Dis Child. 1993;68:177–81. doi: 10.1136/adc.68.2.177
10. Ronnblom A, Forsberg H, Danielsson A. Gastrointestinal symptoms in myotonic dystrophy. Scand J Gastroenterol. 1996;31:654–7. doi: 10.3109/00365529609009145
11. Herner, B. A family with dystrophia myotonica. Acta Med Scand. 1940;CV:17–42. doi: 10.1111/j.0954-6820.1940.tb16079.x
12. Harley HG, Brook JD, Rundle SA, Crow S, Reardon W, Buckler AJ, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature. 1992;355:545–6. doi: 10.1038/355545a0
13. Lexell J, Forsberg H, Krylborg E, Wallmark I, Andersson S, Engstrom M, et al. [Rehabilitation in dystrophia myotonica. A successful experiment with an interdisciplinary team in Norrbotten]. Lakartidningen. 1999;96:4337–40.
14. SCB/Statistics Sweden. Stockholm Available from: https://www.scb.se/contentassets/005dd496170944a3a21d565501569b5d/be0701_2015a01_br_be51br1602.pdf
15. Wahbi K, Porcher R, Laforet P, Fayssoil A, Becane HM, Lazarus A, et al. Development and validation of a new scoring system to predict survival in patients with myotonic dystrophy type 1. JAMA Neurol. 2018;75: 573–81. doi: 10.1001/jamaneurol.2017.4778
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.
